Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Mech Dev. 2009 Mar 4;126(5-6):337–349. doi: 10.1016/j.mod.2009.02.005

Figure 1. NRAGE morpholino dampens NRAGE expression and p38MAPK activation.

Figure 1

(A) NRAGE co-immunoprecipitates with members of the non-canonical BMP pathway. Lysates from 10 ng/ml BMP7 treated mIMCD-3 cells were co-immunoprecipitated with NRAGE antibody and subjected to western blot analysis. The resulting blots were probed for TAB1, TAK1, and XIAP. (B) NRAGE expression is dampened upon treatment with morpholinos against NRAGE. Immunoblot analysis of lysates generated from mIMCD-3 cells treated for 1 hour with 10 ng/ml recombinant BMP7 after being treated with either NRAGE morpholino or with negative control morpholino for 48 hours. (C) p38MAPK activation (p38MAPK-P) is decreased with NRAGE morpholino treatment. Immunoblot analysis of lysates generated from mIMCD-3 cells treated for 1 hour with 10 ng/ml recombinant BMP7 after being treated with either NRAGE morpholino or with negative control morpholino for 48 hours.